Vaccibody has decided to change its financial reporting from NGAAP (Norwegian Generally Accepted Accounting Principles) and instead adopt IFRS (International Financial Reporting Standards) as its new accounting standard.
Vaccibody has experienced a continued growing international interest in its stock, including a significant increase in its international investor base which has led to the company’s decision to change its accounting standard to IFRS.
Read more: Vaccibody enters agreement with Genentech and accelerates R&D programs
In addition, Vaccibody has initiated a process to explore a possible listing of Vaccibody on the Nasdaq Global Market in the United States. This process reflects the continued clinical and strategic advancement of Vaccibody’s portfolio of innovative vaccines and novel immunotherapies as well as the growing interest of international investors in Vaccibody, the company states in a press release.
Read more: Interview – Caspar Foghsgaard, Head of Business Development, Vaccibody
Photo of Michael Engsig, CEO, Vaccibody